Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study: https://t.co/CKpkGF9w8b

The company received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19.

$EDSA #biotech #stocks #covid19 https://t.co/gyLEJHcAw2